Clinical Trial Update: BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial assessing BIBW 2992 (afatinib) plus simvastatin versus BIBW 2992 alone in previously treated advanced non-adenocarcinomatous non-small cell lung c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BIBW 2992 (afatinib)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED